

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶ : A61K 31/715, C08B 37/16	A1	(11) International Publication Number: WO 99/42111 (43) International Publication Date: 26 August 1999 (26.08.99)
(21) International Application Number: PCT/IS99/00003 (22) International Filing Date: 16 February 1999 (16.02.99) (30) Priority Data: 60/075,544 23 February 1998 (23.02.98) US (71) Applicant: CYCLOPS, EHF. [IS/IS]; Borgartun 7, IS-105 Reykjavik (IS). (72) Inventors: LOFTSSON, Thorsteinn; Sorlaskjol 44, IS-107 Reykjavik (IS). MASSON, Mar; Fjolsnisvegur 1, IS-101 Reykjavik (IS). STEFANSSON, Einar; Fjardaras 13, IS-110 Reykjavik (IS). (74) Agent: LOFTSSON, Thorsteinn; University of Iceland, Dept. of Pharmacy, Hagi at Hofsvallagata, P.O. Box 7210, IS-127 Reykjavik (IS).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: HIGH-ENERGY CYCLODEXTRIN COMPLEXES (57) Abstract Methods for enhancing the complexation efficiency of a drug with cyclodextrin and for enhancing the availability of a drug following administration of a cyclodextrin-drug complex.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

HIGH-ENERGY CYCLODEXTRIN COMPLEXES

BACKGROUND OF THE INVENTION

Field of the Invention:

The invention relates to methods for enhancing the complexation of a
5 heterocyclic drug with cyclodextrin and to methods for enhancing the availability
of a heterocyclic drug following administration of a cyclodextrin-drug complex.

Background Art:

Cyclodextrins are a group of structurally related saccharides which are
formed by enzymatic cyclization of starch by a group of amylases termed
10 glycosyltransferases. Cyclodextrins are cyclic oligosaccharides, consisting of (α -
1,4)-linked α -D-glucopyranose units, with a somewhat lipophilic central cavity and
a hydrophilic outer surface. The most common naturally occurring cyclodextrins
are α -cyclodextrin, β -cyclodextrin and γ -cyclodextrin consisting of 6, 7 and 8
glucopyranose units, respectively. Of these three derivatives, β -cyclodextrin
15 appears to be the most useful pharmaceutical complexing agent due to its cavity
size, availability, low cost and other properties.

The natural cyclodextrins, in particular β -cyclodextrin, have limited
aqueous solubility and their complex formation with lipophilic drugs often results
in precipitation of solid drug-cyclodextrin complexes. Thus, the solubility of β -
20 cyclodextrin in water is only about 18.5 mg/ml at room temperature. This low
aqueous solubility is, at least partly, associated with strong intramolecular
hydrogen bonding in the cyclodextrin crystal lattice. Substitution of any of the
hydrogen bond-forming hydroxyl groups, even by hydrophobic moieties such as
methoxy groups, will increase the aqueous solubility of β -cyclodextrin. In
25 addition, since these manipulations frequently produce large numbers of isomeric

-2-

products, chemical modification can transform the crystalline cyclodextrins into amorphous mixtures increasing their aqueous solubility.

Cyclodextrin derivatives of current pharmaceutical interest include the hydroxypropyl derivatives of α -, β - and γ -cyclodextrin, sulfoalkylether cyclodextrins such as sulfobutylether β -cyclodextrin, alkylated cyclodextrins such as the randomly methylated β -cyclodextrin, and various branched cyclodextrins such as glucosyl- and maltosyl- β -cyclodextrin (T. Loftsson and M.E. Brewster, "Cyclodextrins as pharmaceutical excipients", *Pharm. Technol. Eur.*, 9(5), 26-34 (1997); T. Loftsson and M.E. Brewster, "Pharmaceutical applications of cyclodextrins. I. Drug solubilization and stabilization", *J. Pharm. Sci.* 85(10), 1017-1025 (1996); R.A. Rajewski and V.J. Stella, "Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery", *J. Pharm. Sci.* 85(11), 1142-1169 (1996); T. Irie and K. Uekama, "Pharmaceutical applications of cyclodextrins. 3. Toxicological issues and safety evaluation", *J. Pharm. Sci.*, 86(2), 147-162 (1997); V.J. Stella and R.A. Rajewski, "Cyclodextrins: their future in drug formulation and delivery", *Pharm. Res.*, 14(5), 556-567 (1997); T. Loftsson, "Increasing the cyclodextrin complexation of drugs and drug bioavailability through addition of water-soluble polymers", *Pharmazie*, 53, 733-740 (1998)).

Preparation of cyclodextrin inclusion complexes

In aqueous solutions, cyclodextrins form complexes with many drugs through a process in which the water molecules located in the central cavity are replaced by either the whole drug molecule, or more frequently, by some lipophilic portion of the drug structure. Once included in the cyclodextrin cavity, the drug molecules may be dissociated through complex dilution, by replacement of the included drug by some other suitable molecule (such as dietary lipids or bile salts in the GI tract) or, if the complex is located in close approximation to a lipophilic biological membrane (such as the mucosal membrane of the GI tract),

-3-

the drug may be transferred to the matrix for which it has the highest affinity. Importantly, since no covalent bonds are formed or broken during the drug-cyclodextrin complex formation, the complexes are in dynamic equilibrium with free drug and cyclodextrin molecules (R.A. Rajewski and V.J. Stella, "Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery", *J. Pharm. Sci.* 85(11), 1142-1169 (1996)).

Various methods have been applied to the preparation of drug-cyclodextrin complexes (T. Loftsson and M.E. Brewster, "Pharmaceutical applications of cyclodextrins. I. Drug solubilization and stabilization", *J. Pharm. Sci.* 85(10), 1017-1025 (1996); T. Loftsson and M.E. Brewster, "Cyclodextrins as pharmaceutical excipients", *Pharm. Technol. Eur.*, 9(5), 26-34 (1997)). In solution, the complexes are usually prepared by addition of an excess amount of the drug to an aqueous cyclodextrin solution. The suspension formed is equilibrated (for periods of up to one week at the desired temperature) and then filtered or centrifuged to form a clear drug-cyclodextrin complex solution. Since the rate determining step in complex formation is often the phase to phase transition of the drug molecule, it is sometimes possible to shorten this process by formation of supersaturated solutions through sonication followed by precipitation. For preparation of the solid complexes, the water is removed from the aqueous drug-cyclodextrin solutions by evaporation or sublimation, e.g. spray-drying or freeze-drying. Other methods can also be applied to prepare solid drug-cyclodextrin complexes including kneading methods, co-precipitation, neutralization and grinding techniques. In the kneading method, the drug is added to an aqueous slurry of a poorly water-soluble cyclodextrin such as β -cyclodextrin. The mixture is thoroughly mixed, often at elevated temperatures, to yield a paste which is then dried. This technique can frequently be modified so that it can be accomplished in a single step with the aid of commercially available mixers which can be operated at temperatures over 100 °C and under vacuum. The kneading

method is a cost-effective means for preparing solid cyclodextrin complexes of poorly water-soluble drugs. Co-precipitation of a cyclodextrin complex through addition of organic solvent is also possible. Unfortunately, the organic solvents used as precipitants can interfere with complexation which makes this approach less attractive than the kneading method. However, we have discovered that some organic solvents under some specific conditions, e.g. 10% (v/v) aqueous acetic acid solution, can enhance the complexation. Solid complexes of ionizable drugs can sometimes be prepared by the neutralization method wherein the drug is dissolved in an acidic (for basic drugs) or basic (for acidic drugs) aqueous cyclodextrin solution. The solubility of the drug is then lowered through appropriate pH adjustments (i.e. formation of the unionized drug) to force the complex out of solution. Finally, solid drug-cyclodextrin complexes can be formed by the grinding of a physical mixture of the drug and cyclodextrin and then heating the mixture in a sealed container to 60 to 90 °C.

15 Methods for enhancing cyclodextrin complexation

For a variety of reasons including cost, production capabilities and toxicology, the amounts of cyclodextrin which can be used in most drug formulations is limited (T. Loftsson and M.E. Brewster, "Cyclodextrins as pharmaceutical excipients", *Pharm. Technol. Eur.*, 9(5), 26-34 (1997); T. Loftsson, "Increasing the cyclodextrin complexation of drugs and drug bioavailability through addition of water-soluble polymers", *Pharmazie*, 53, 733-740 (1998)).

If one drug molecule (D) forms a complex with one cyclodextrin molecule (CD), then the complexation efficiency ($[D-CD]/[CD]$) will be equal to the intrinsic solubility of the drug (S_0) times the stability constant of the drug-cyclodextrin complex (K_C). In aqueous cyclodextrin solutions saturated with drug, the concentration of free drug ($[D]$) is approximately equal to S_0 . Thus,

-5-

increased complexation efficiency can be obtained by either increasing S_0 or by increasing K_C or by increasing both simultaneously. Addition of organic solvents, such as ethanol, to the aqueous complexation media can result in enhanced complexation efficiency through increase in S_0 . Drug ionization can increase the complexation efficiency through increase in S_0 . Addition of certain low molecular weight acids, such as acetic, citric, malic, or tartaric acid, to aqueous complexation media can enhance cyclodextrin solubilization of basic drugs through increase in S_0 (i.e. salt formation, pH changes and lowering melting point) and/or increase in the apparent K_C . Water-soluble polymers can increase the complexation efficiency through increase in the apparent K_C . Furthermore, it is often possible to enhance cyclodextrin complexation even further by using several different methods simultaneously to enhance the cyclodextrin complexation. Pharmaceutical applications of these and other methods have been reviewed (See T. Loftsson, "Increasing the cyclodextrin complexation of drugs and drug bioavailability through addition of water-soluble polymers", *Pharmazie*, 53, 733-740 (1988); T. Loftsson and M.E. Brewster, "Cyclodextrins as pharmaceutical excipients", *Pharm. Technol. Eur.*, 9(5), 26-34 (1997); T. Loftsson and M.E. Brewster, "Pharmaceutical applications of cyclodextrins. I. Drug solubilization and stabilization", *J. Pharm. Sci.* 85(10), 1017-1025 (1996)).

20 Permeability of drugs through biological membranes

The cyclodextrin molecules are relatively large (molecular weight ranging from almost 1000 to over 1500), with a hydrated outer surface, and under normal conditions, cyclodextrin molecules will only permeate biological membranes with considerable difficulty (R.A. Rajewski and V.J. Stella, "Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery", *J. Pharm. Sci.* 85(11), 1142-1168 (1996); T. Irie and K. Uekama, "Pharmaceutical applications of cyclodextrins. 3. Toxicological issues and safety evaluation", *J. Pharm. Sci.*

-6-

86(2), 147-162 (1997); K.-H. Frömning and J. Szejtli, *Cyclodextrins in pharmacy*, Kluwer Academic Publishers, Dordrecht, The Netherlands, 1994; T. Loftsson and J.H. Ólafsson, "Cyclodextrins: new drug delivery systems in dermatology", *Int. J. Dermatol.*, 37, 241-246 (1998); T. Loftsson and E. Stefánsson, "Effect of cyclodextrins on topical drug delivery to the eye", *Drug Dev. Ind. Pharm.* 23(5), 473-481 (1997)). It is generally recognized that cyclodextrins act as true carriers by keeping the hydrophobic drug molecules in solution and deliver them to the surface of the biological membrane, e.g. skin, mucosa or the eye cornea, where they partition into the membrane. The relatively lipophilic membrane has low affinity for the hydrophilic cyclodextrin molecules and therefore they remain in the aqueous membrane exterior, e.g. the aqueous vehicle system, saliva or the tear fluid. Conventional penetration enhancers, such as alcohols and fatty acids, disrupt the lipid layers of the biological barrier. Cyclodextrins, on the other hand, act as penetration enhancers by increasing drug availability at the surface of the biological barrier. Furthermore, addition of water-soluble polymer, such as polyvinylpyrrolidone, apparently increase even further the availability of the drug molecules at the surface of the biological membrane resulting in enhanced drug bioavailability (T. Loftsson, "Increasing the cyclodextrin complexation of drugs and drug bioavailability through addition of water-soluble polymers", *Pharmazie*, 53, 733-740 (1998); T. Loftsson, M. Másson and E. Stefánsson, "Cyclodextrins as Permeation enhancers", *Proceedings of the 17th Pharmaceutical Technology Conference and Exhibition*, Volume 2, Dublin, 24-26 March, 1998, pp. 313-324).

OBJECTS AND SUMMARY OF THE INVENTION

25 Enhancing complexation efficiency

It is possible to enhance the cyclodextrin (CD) complexation efficacy, or efficiency, of drugs (D), and other "guest" molecules, by either increasing the

-7-

apparent stability constant (K_C) of the drug-cyclodextrin complex (D-CD) or increasing the apparent intrinsic solubility (S_0) of the drug. For example, K_C can be increased by addition of water-soluble polymers to the aqueous complexation media and S_0 can be increased by ionization of the drug molecule, as described previously. However, increased complexation efficiency by itself does not necessarily result in increased drug availability in the aqueous complexation media or increased drug availability from solid drug-cyclodextrin complexes. On the other hand, if the drug-cyclodextrin complexes are prepared under conditions which ensure enhanced complexation and if the complexation efficiency decreases upon administration, then enhanced drug availability will be observed. Thus, the present invention involves: i) enhancement of the complexation efficiency and ii) reduction of the complexation efficiency after administration. For example, it is possible to enhance the complexation efficiency of many ionizable drugs by preparing the complexes at a pH where the drug is ionized but obtain decreased efficiency upon administration due to pH changes and consequent decreased ionization. One example of such a drug is phenytoin (pKa 8.1). Its solubility in water at room temperature (25 °C) is only 18 $\mu\text{g/ml}$ at pH 5 and 32 $\mu\text{g/ml}$ at pH 8 (P.A. Schwartz, C.T. Rhodes and J.W. Cooper, "Solubility and ionisation characters of phenytoin", *J. Pharm. Sci.* 66, 994-997 (1977)). Addition of 25% (w/v) 2-hydroxypropyl- β -cyclodextrin to the aqueous solutions increases the solubility of phenytoin to 5.0 mg/ml at pH 5 and 6.4 mg/ml at pH 8, which is 280- and 200-fold solubility enhancement, respectively. Although the apparent stability constant (K_C) of the phenytoin-cyclodextrin complex is much larger for the drug in the unionized form than for the anionic form, it is possible to obtain much higher total solubility by increasing the apparent intrinsic solubility (S_0) of the drug (T. Loftsson and N. Bodor, "Effects of 2-hydroxypropyl- β -cyclodextrin on the aqueous solubility of drugs and transdermal delivery of 17 β -estradiol", *Acta Pharm. Nord.*, 1, 185-194 (1989)). However, if the pH 8.0 solution was placed in

-8-

an environment which would decrease the pH from 8 to 5 (e.g. topical application to the skin), then a supersaturated solution would be formed which would result in enhanced drug availability (e.g. it would result in enhanced transdermal drug delivery). Other means to enhance S_0 include reversible derivation (e.g. prodrug formation) of the guest molecule and addition of certain low molecular weight acids. The value of K_C can, for example, be increased by addition of certain low molecular weight acids, by addition of water-soluble polymers to the aqueous complexation media or by using mixed solvent systems such as aqueous 10% (v/v) acetic acid. For example, addition of the polymers and heating in an autoclave (to 120-140°C for 20-40 minutes) does not only increase the complexation but it has also been shown to enhance transdermal and transcorneal drug delivery (T. Loftsson and A.M. Sigurdardottir, "Cyclodextrins as skin penetration enhancers", in J. Szejtli and L. Szente (Eds.) *Proceedings of the Eighth International Symposium on Cyclodextrins*, Kluwer Academic Publishers, 1996, pp. 403-406; T. Loftsson and E. Stefansson, "Effect of cyclodextrins on topical drug delivery to the eye", *Drug Devel. Ind. Pharm.*, 23(5), 473-481 (1997)). As shown in Table 1 below, it is not enough to add the polymers to the complexation medium. Addition of polymers to the unheated vehicles did not enhance the transdermal delivery of enalaprilat. However, heating the vehicles after addition of the polymers resulted in significant enhancement. The effect of the polymers on the transdermal delivery of enalaprilat can, at least partly, be explained by decreased complexation efficiency (i.e. decrease in K_C) at the skin surface.

Table 1. The effect of heating on transdermal delivery of enalaprilat from 10% (w/v) HP β CD solutions at pH 5.0 containing 2.5% enalaprilat in a suspension. The concentration of dissolved enalaprilat was between 2.0 and 2.3% (w/v).

5	Donor phase (w/v per cent)	Flux (mg h ⁻¹ cm ⁻²)		Ratio
		Un-heated	Heated	
	HP β CD	18 \pm 2	-	-
	HP β CD, 0.25% PVP	16 \pm 6	23 \pm 7	1.4
10	HP β CD, 0.10% HPMC	14 \pm 3	37 \pm 12	2.6

In one aspect of the present invention there is provided a method for enhancing the complexation efficacy, i.e. efficiency, of a drug with cyclodextrin, said drug having a structure comprising at least one heterocyclic ring having a total of from 4 to 7 ring atoms, of which from 1 to 3 are hetero ring atoms, each of said hetero ring atoms being selected from nitrogen, oxygen and sulfur, said ring being a cyclic imine, enamine, lactone, lactam, thiolactam, anhydride, imide, hemiacetal or hemiketal, said method comprising subjecting said drug to chemically reversible ring-opening so that at least a portion (at least 0.1% by weight) thereof is in ring-opened form, and complexing said drug with cyclodextrin.

In a related aspect of the invention, there is provided a method for enhancing the complexation efficiency of a drug with cyclodextrin, said drug having a structure comprising at least one heterocyclic ring having a total of from 4 to 7 ring atoms, of which from 1 to 3 are hetero ring atoms, each of said hetero ring atoms being selected from nitrogen, oxygen and sulfur, said ring being a cyclic imine, enamine, lactone, lactam, thiolactam, anhydride, imide, hemiacetal

-10-

or hemiketal, said method comprising complexing said drug with cyclodextrin in an aqueous medium under conditions which effect chemically reversible ring-opening of at least a portion (at least 0.1% by weight) of said drug.

5 In another aspect of the invention, there is provided a method for enhancing the availability of a drug following administration of a cyclodextrin-drug complex to a warm-blooded animal in need of same, said drug having a structure comprising at least one heterocyclic ring having a total of from 4 to 7 ring atoms of which from 1 to 3 are hetero ring atoms, each of said hetero ring atoms being selected from nitrogen, oxygen and sulfur, said ring being a cyclic
10 imine, enamine, lactone, lactam, thiolactam, anhydride, imine, hemiacetal or hemiketal, said method comprising complexing said drug with cyclodextrin in an aqueous medium under conditions which effect chemically reversible ring-opening of at least a portion (at least 0.1% by weight) of said drug to enhance the complexation efficiency, followed by administering the cyclodextrin-drug complex
15 thus obtained to said animal under conditions which reduce the complexation efficiency.

In still another aspect, the present invention provides a method for enhancing the availability of a basic drug (i.e. a proton acceptor) following administration of a cyclodextrin-drug complex to a warm-blooded animal in need
20 of same, said basic drug having a structure comprising at least one heterocyclic ring having a total of from 4 to 7 ring atoms, of which from 1 to 3 are hetero ring atoms, each of said hetero ring atoms being selected from nitrogen, oxygen and sulfur, said ring being a cyclic imine, enamine, lactone, lactam, thiolactam, anhydride, imide, hemiacetal or hemiketal, said method comprising subjecting said
25 basic drug to complexation in an aqueous medium at a pH level below the $pK_a + 2$ value of said basic drug to enhance the complexation efficiency, followed by administering the cyclodextrin-drug complex thus obtained to said animal under conditions which reduce the complexation efficiency.

-11-

In yet another aspect, the present invention provides a method for enhancing the availability of an acidic drug following administration of a cyclodextrin-drug complex to a warm-blooded animal in need of same, said acidic drug having a structure comprising at least one heterocyclic ring having a total of 4 to 7 ring atoms, of which from 1 to 3 are hetero ring atoms, each of said hetero ring atoms being selected from nitrogen, oxygen and sulfur, said ring being a cyclic imine, enamine, lactone, lactam, thiolactam, anhydride, imide, hemiacetal or hemiketal, said method comprising subjecting said acidic drug to complexation in an aqueous medium at a pH level above the pKa-2 value of said acidic drug to enhance the complexation efficiency, followed by administering the cyclodextrin-drug complex thus obtained to said animal under conditions which reduce the complexation efficiency.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a graph illustrating the effect of pH on the phase-solubility of phenytoin (pKa 8.1) in aqueous hydroxypropyl- β -cyclodextrin (HP β CD) solutions at 25°C at pH 10.19 (◆); pH 7.55 (■) and pH 2.74 (●);

Fig. 2 is a graph illustrating the effect of pH on the solubility of alprazolam (pKa 2.4) in aqueous 10% (w/v) HP β CD solutions at room temperature;

Fig. 3 is a graph illustrating the effect of pH (i.e. the diazepine ring-opening) on the solubility of midazolam (pKa 6.2) in pure aqueous buffer solutions (●), aqueous buffer solutions containing 10% (w/v) HP β CD (■) and aqueous buffer solutions containing both 10% (w/v) HP β CD and 0.10% (w/v) hydroxypropyl methylcellulose (HPMC) (◆) at room temperature;

Fig. 4 is a graph illustrating the effects of cyclodextrins, pH and 10% (v/v) acetic acid on the solubility of midazolam in aqueous solutions: pure aqueous buffer solution (▲); aqueous 10% (v/v) acetic acid solution (●); 10% w/v HP β CD solution containing 0.10% (w/v) HPMC in aqueous 10% (v/v) acetic acid solution

-12-

(■); 10% (w/v) aqueous sulfobutyl ether- β -cyclodextrin (SBE β CD) solution in aqueous 10% (v/v) acetic acid solution (◆); and

5 Fig. 5 is a graph plotting the concentration in ng/ml of midazolam in serum after intravenous administration of 2 mg of a commercial intravenous formulation of midazolam (○) and nasal administration of 4.8 mg of a nasal formulation of midazolam prepared in accord with the present invention (Δ), against time in minutes, where each point represents the mean value and error bars represent standard deviation.

DETAILED DESCRIPTION OF THE INVENTION

10 The following table (Table 2) lists some of the currently available cyclodextrins contemplated for use in the present invention.

Table 2. Some of the currently available cyclodextrins obtained by substitution of the OH-groups located on the edge of the cyclodextrin ring. Since both the number of substituents and their location will affect the physicochemical properties of the cyclodextrin molecules, such as their aqueous solubility and complexing abilities, each derivative listed should be regarded as a group of closely related cyclodextrin derivatives.

Type	α -Cyclodextrin derivatives	β -Cyclodextrin derivatives	γ -Cyclodextrin derivatives
Alkylated:	Methyl Butyl	Methyl Ethyl Butyl	Methyl Butyl Pentyl
Hydroxylalkylated:	2-Hydroxypropyl	Hydroxyethyl 2-Hydroxypropyl 2-Hydroxybutyl	Hydroxyethyl 2-Hydroxypropyl
Esterified:	Acetyl Succinyl	Acetyl Propionyl Butyryl Succinyl Benzoyl Palmityl Toluenesulfonyl	Acetyl Succinyl
Esterified and alkylated:		Acetyl methyl Acetyl butyl	
Branched:	Glucosyl Maltosyl	Glucosyl Maltosyl	Glucosyl Maltosyl
Ionic:	Carboxymethyl ether Phosphate ester	Carboxymethyl ether Carboxymethyl ethyl Phosphate ester 3-Trimethylammonium-2-hydroxypropyl ether Sulfobutyl ether	Carboxymethyl ether Phosphate ester
Polymerized:	Simple polymers Carboxymethyl	Simple polymers Carboxymethyl	Simple polymers Carboxymethyl

-14-

Particularly preferred cyclodextrins for use herein are hydroxypropyl- β -cyclodextrin, β -cyclodextrin sulfobutyl ether, the branched β -cyclodextrins (especially glucosyl- β -cyclodextrin and maltosyl- β -cyclodextrin), β -cyclodextrin, hydroxypropyl- γ -cyclodextrin and γ -cyclodextrin.

5 In preferred aspects of the present invention, the drug for use herein is one having a structure comprising at least one heterocyclic ring. The heterocyclic ring generally has a total of 4 to 7 ring atoms, of which from 1 to 3 are hetero ring atoms. While each hetero ring atom can be nitrogen, oxygen or sulfur, heterocycles having at least one nitrogen or oxygen ring atom are preferred.

10 Preferably, the drug has at least one heterocyclic ring which is a cyclic imine, enamine, lactone, lactam, thiolactam, anhydride, imide, hemiacetal or hemiketal.

Especially desirable drugs for use in accord with the present invention are benzodiazepines. Benzodiazepines contain a benzene ring fused with a diazepine ring which is a 7-membered ring with nitrogen atoms in positions 1 and 4. By

15 way of example, the chemical name of alprazolam is 8-chloro-1-methyl-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine, the chemical name of midazolam is 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine and that of triazolam is 8-chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo[4,3-

20 a][1,4]benzodiazepine. Thus, all of these compounds have the 1,4-benzodiazepine structure with a double bond between nitrogen atom number 4 and carbon atom number 5 (which gives the molecule a cyclic imine structure). The benzodiazepines are cyclic imines. They are all basic, i.e. they are proton acceptors. Preferred benzodiazepines for use herein are alprazolam, brotizolam, chlordiazepoxide, clobazam, clonazepam, clorazepam, demoxazepam, flumazenil,

25 flurazepam, halazepam, midazolam, nordazepam, medazepam, diazepam, nitrazepam, oxazepam, midazepam, lorazepam, prazepam, quazepam, triazolam, temazepam and lorazepam. Especially preferred are midazolam, alprazolam, clonazepam, lorazepam and triazolam.

-15-

Another group of preferred drugs for use herein consists of the barbituric acid derivatives. The barbituric acids contain a 2,4,6-trihydroxypyrimidine (also called 2,4,6-trioxohexahydropyrimidine) ring in their structure, a 6-member ring with nitrogen in positions 1 and 3. Thus, the chemical name of barbital is 5,5-diethyl-2,4,6(1H,3H,5H)-pyrimidinetrione and that of phenobarbital is 5-ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione. The barbituric acids can be characterized as cyclic amides or lactams (cyclic amides are called lactams) or imides (which are nitrogen analogues of cyclic anhydrides). Barbituric acids are weak acids. Preferred barbituric acid derivatives are barbital, butobarbital, amobarbital, phenobarbital, aprobarbital, secobarbital, crotylbarbital, cyclobarbital, phenobarbital, hexobarbital, methylphenobarbital, thiopental, isopropylbromallylbarbituric acid, cyclohexenylallylthiobarbituric acid and their salts. Thiopental is 5-ethyl-5-(1-methylbutyl)-2-thioxo-4,6(1H,5H)-pyrimidinedione, i.e. one = O moiety in the barbituric acid structure has been replaced by = S.

Yet another group of preferred drugs for use in the present invention consists of the hydantoins. Hydantoins are, like barbituric acids, cyclic urea derivatives. The ring-opened acyl derivatives of hydantoins and barbituric acids are sometimes called ureides. Both hydantoins and barbituric acids can form urea upon hydrolysis. Hydantoins contain a 2,4-imidazolidinedione ring in their structure, a 5-membered ring with nitrogen in positions 1 and 3. The chemical name of, for example, phenytoin, is 5,5-diphenyl-2,4-imidazolidinedione. Hydantoins are closely related to barbituric acids and are acids like them.

Still another group of preferred drugs for use in the present invention consists of pyrazole derivatives. The expression "pyrazole derivatives" as used herein includes drugs containing a pyrazole ring, 3-pyrazoline ring or pyrazolidine ring in their structure, all of which are 5-membered rings with nitrogens in positions 1 and 2. These compounds are either basic or acidic. Preferred pyrazole

-16-

derivatives for use herein include phenazone, phenylphenazone, metamidazole, phenylbutazone, oxyphenbutazone and sulfinpyrazone.

Yet another group of drugs preferred for use herein consists of imidazole derivatives. The expression "imidazole derivatives" as used herein includes drugs
5 containing an imidazole, imidazoline or imidazolidine ring in their structure. These are 5-membered rings with nitrogen atoms in positions 1 and 3. These compounds are either basic or acidic. Preferred compounds of this type include histamine, miconazole, pilocarpine, naphazoline and clonidine.

Another group of preferred drugs for use in this invention are pyrimidine
10 derivatives. These drugs contain a 6-membered ring with nitrogen atoms in positions 1 and 3. These derivatives are usually basic. Preferred pyrimidine derivatives include thiamine, trimethoprim, orotic acid, methylthiouracyl and prothiouracyl.

Still another group of preferred drugs for use herein are purine derivatives,
15 which contain purine, that is, imidazo(4,5-d)pyrimidine, in their structures. These drugs are frequently basic but some of them are acidic. Preferred purine derivatives include caffeine, theophylline, etophylline, proxyphylline and theobromine.

~~Cyclic drugs having heterocyclic rings characterized as enamines, lactones,~~
20 lactams, thiolactams, anhydrides, imides, imines, hemiacetals and hemiketals are thus appropriate for use in preferred embodiments of the invention, in which ring opening of the heterocyclic ring takes place.

In various aspects of the present invention, the drug is subjected to chemically reversible ring-opening so that at least a portion thereof is in
25 ring-opened form. The portion in ring-opened form is at least 0.1 % by weight, preferably at least 1 or 2 % by weight, more preferably at least 5 % by weight of said drug. In aqueous formulations, the amount of drug in ring-opened form is frequently from about 5 to about 10 % by weight and usually no more than about

-17-

50%. In solid formulations, the portion of drug in ring-opened form can generally be much higher, frequently about 50% or more, and sometimes even about 90 to 95%.

5 When the method of the invention comprises complexing the drug with cyclodextrin in an aqueous medium under conditions which effect chemically reversible ring-opening of at least a portion (at least 0.1% by weight) of the drug, the complexation is advantageously conducted at a pH level which affords ring-opening of at least 5% by weight of said drug. Preferably the complexation is conducted at a pH level of below about 5.

10 In one preferred embodiment, the drug is a basic drug, especially a benzodiazepine, and the complexation is conducted at a pH level of below about 5. It is also preferred that the cyclodextrin is hydroxypropyl- β -cyclodextrin, β -cyclodextrin sulfobutyl ether, a branched β -cyclodextrin (especially glucosyl β -cyclodextrin or maltosyl- β -cyclodextrin), β -cyclodextrin, hydroxypropyl- γ -
15 cyclodextrin or γ -cyclodextrin. It is also preferred that the benzodiazepine is alprazolam, brotizolam, chlordiazepoxide, clobazam, clonazepam, clorazepam, demoxazepam, flumazenil, flurazepam, halazepam, midazolam, nordazepam, medazepam, diazepam, nitrazepam, oxazepam, midazepam, lorazepam, prazepam, quazepam, triazolam, temazepam or lorazepam; and that the cyclodextrin-drug
20 complex thus obtained be formulated as a nasal spray, sublingual tablet or parenteral solution, especially when formulated suitable for use in producing a sedative, anti-anxiety, anticonvulsant or muscle relaxant effect, most especially as a pre-anaesthetic medication, or to supplement anaesthesia, to induce and/or maintain anaesthesia or to induce a hypnotic effect. In especially preferred
25 embodiments, the benzodiazepine is midazolam, alprazolam, clonazepam, lorazepam or triazolam; the cyclodextrin is hydroxypropyl- β -cyclodextrin, β -cyclodextrin sulfobutyl ether, a branched β -cyclodextrin (especially glucosyl β -cyclodextrin or maltosyl β -cyclodextrin), β -cyclodextrin, hydroxypropyl- γ -

-18-

cyclodextrin or γ -cyclodextrin; and the complexation is conducted at a pH level below about 5, preferably between about 3 and about 5.

In another embodiment of the present method utilizing chemically reversible ring-opening described above, the drug is an acidic drug.

5 In yet another embodiment of the present method utilizing chemically reversible ring-opening described above, the drug is a barbituric acid derivative, a hydantoin, a pyrazole derivative, an imidazole derivative, a pyrimidine derivative or a purine derivative. When the drug is a barbituric acid derivative, it is preferably barbitol, butobarbital, amobarbital, phenobarbital, aprobarbital, 10 secobarbital, crotylbarbital, cyclobarbital, phenobarbital, hexobarbital, methylphenobarbital, thiopental, isopropylbromallylbarbituric acid, or cyclohexenylallylthiobarbituric acid, or a salt thereof. When the drug is a hydantoin, it is preferably phenytoin. When the drug is a pyrazole derivative, it is preferably phenazone, propylphenazone, metamidazole, phenylbutazone, 15 oxyphenbutazone or sulfinpyrazone. When the drug is an imidazole derivative, it is preferably histamine, miconazole, pilocarpine, naphazoline or clonidine. When the drug is a pyrimidine derivative, it is preferably thiamine, trimethoprim, orotic acid, methylthiouracyl or prothiouracyl. When the drug is a purine derivative, it is preferably caffeine, theophylline, etophylline, proxiphylline or theobromine.

20 When the present invention comprises complexing the drug with cyclodextrin in an aqueous medium under conditions which effect chemically reversible ring-opening of at least a portion (at least 0.1 % by weight) of the drug to enhance the complexation efficacy, followed by administering the cyclodextrin-drug complex thus obtained to said animal under conditions which 25 reduce the complexation efficacy, the complexation is generally conducted at a pH level which affords ring-opening of at least 5 % by weight of the drug. Preferably, the complexation is conducted at a pH level of below about 5, especially between about 3 and about 5. The cyclodextrin is preferably hydroxypropyl- β -

-19-

cyclodextrin, β -cyclodextrin sulfobutyl ether, a branched β -cyclodextrin (especially glucosyl- β -cyclodextrin or maltosyl- β -cyclodextrin), β -cyclodextrin, hydroxypropyl- γ -cyclodextrin or γ -cyclodextrin. The drug is preferably a benzodiazepine, especially midazolam, alprazolam, clonazepam, lorazepam or triazolam. The cyclodextrin-drug complex is preferably administered in the form of an aqueous solution or a hydrogel, particularly as a nasal spray or nasal drops, or as a parenteral solution. As a nasal spray of a benzodiazepine, the aqueous solution is advantageously brought to a pH level of below about 6, preferably below about 4.7, most especially to a pH between about 3 and about 4.7. When administered as a solid, the cyclodextrin-drug complex is preferably formulated as a tablet for oral, buccal or sublingual administration. The water may be removed from the aqueous complexation medium after formation of the cyclodextrin-drug complex.

When the present invention comprises subjecting a basic drug to complexation in an aqueous medium at a pH level below the $pK_a + 2$ value of said basic drug to enhance the complexation efficiency, followed by administering the cyclodextrin-drug complex thus obtained to an animal under conditions which reduce the complexation efficiency, the basic drug is preferably a benzodiazepine. Benzodiazepines of particular interest are alprazolam, brotizolam, chlordiazepoxide, clobazam, clonazepam, clorazepam, demoxazepam, flumazenil, flurazepam, halazepam, midazolam, nordazepam, medazepam, diazepam, nitrazepam, oxazepam, midazepam, lorazepam, prazepam, quazepam, triazolam, temazepam and loprazolam. Particularly preferred benzodiazepines are alprazolam, midazolam, clonazepam, lorazepam and triazolam. The cyclodextrin-benzodiazepine complex obtained in the complexation step is preferably formulated as a nasal spray, sublingual tablet or parenteral solution, which is preferably administered in an effective sedative, anti-anxiety, anticonvulsant or muscle relaxant amount, particularly as a pre-anaesthetic

-20-

medication, or to supplement anaesthesia, to induce and/or maintain anaesthesia or to induce a hypnotic effect. In this general aspect of the invention, the pH level of the aqueous complexation medium is advantageously selected so that it also affords ring-opening of at least 5% by weight of the drug. For the

5 benzodiazepines, the complexation is preferably conducted at a pH level of below about 5, most preferably between about 3 and about 5. Also in this general aspect of the invention, in one preferred embodiment, the complexation is carried out in the presence of from about 0.001 to about 5% (weight/volume) of a pharmacologically inactive, pharmaceutically acceptable water-soluble polymer at

10 a temperature of from about 30°C to about 150°C. Preferably, the polymer is a cellulose derivative or a polyvinyl polymer; more preferably, the polymer is methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl methylcellulose, hydroxypropyl ethylcellulose, hydroxyethyl ethylcellulose, sodium carboxymethylcellulose or

15 polyvinylpyrrolidone. An especially preferred cellulose derivative is hydroxypropyl methylcellulose. A method for enhancing drug-cyclodextrin complexation utilizing a pharmacologically inactive water-soluble polymer is described in Loftsson United States Patents No. 5,324,718 and No. 5,472,954. In another preferred embodiment of this general aspect of the invention, the

20 complexation is also carried out in the presence of acetic acid and/or one or more pharmaceutically acceptable salts of acetic acid, the acetate-water ratio of the aqueous complexation medium being from about 1:1000 to about 2:1, preferably from about 1:100 to about 1:1, more preferably from about 1:20 to about 1:4. Preferably, the drug is midazolam and the cyclodextrin is hydroxypropyl- β -

25 cyclodextrin, β -cyclodextrin sulfobutyl ether, a branched β -cyclodextrin (especially glucosyl- β -cyclodextrin or maltosyl- β -cyclodextrin), β -cyclodextrin, hydroxypropyl- γ -cyclodextrin or γ -cyclodextrin.

-21-

When the present invention comprises subjecting an acidic drug to complexation in an aqueous medium at a pH level above the pK_a -2 value of said acidic drug to enhance the complexation efficiency, followed by administering the cyclodextrin-drug complex thus obtained to an animal under conditions which
5 reduce the complexation efficiency, preferably the pH level of the aqueous complexation medium is selected such that it also affords ring-opening of at least 5% by weight of said drug.

In order to further illustrate the present invention and the advantages thereof, the following specific examples are given, it being understood that same
10 are intended only as illustrative and in no way limitative of the invention.

Example 1

Phenytoin (5,5-diphenylhydantoin) is a water-insoluble weak acid (pK_a 8.1) which forms a somewhat water-soluble anion in alkaline solution. Solubility (S) of phenytoin at three different pH levels was determined in aqueous solutions
15 containing various amounts of 2-hydroxypropyl- β -cyclodextrin (HP β CD) of molar substitution (MS) = 0.9, i.e. (a) pH 2.74 ± 0.18 (SD), (b) pH 7.55 ± 0.12 , and (c) pH 10.19 ± 0.14 . Excess amount of the drug was added to the aqueous HP β CD solution and the suspension formed sonicated for one hour at room temperature
(23°C). After equilibration at 25°C in a water-bath for three days, the suspension
20 was filtered through a 0.45 μ m membrane filter, diluted with aqueous methanolic solution and the amount of dissolved phenytoin determined by a high pressure liquid chromatographic method (HPLC). FIG. 1 illustrates the effect of pH on the phase-solubility of phenytoin (pK_a 8.1) in aqueous HP β CD solutions at 25°C. The results set forth in FIG. 1 show significant enhancement in the HP β CD
25 solubilization (i.e. the efficiency of the complexation) of the drug at pH 10.19 (♦) where the drug is mainly in the ionized form. Formation of phenytoin-HP β CD complexes at pH 10.19 can result in enhanced bioavailability of phenytoin. For

-22-

example, topical application of such a solution to the skin will result in lowering of pH, which will decrease the efficiency of the complexation, which again will result in enhanced permeability of phenytoin into and through the skin. Also, formation of phenytoin-HP β CD complexes at pH of about 10 (e.g. in aqueous ammonia solutions) and lyophilization of the complex will result in phenytoin-HP β CD complex powder which can, for example, be formulated into tablets. The bioavailability of phenytoin from such tablets will be enhanced compared to the phenytoin availability from tablets containing phenytoin-HP β CD complex prepared at lower pH, e.g. at pH 2.7 (●) or 7.6 (■).


10 **Example 2**

Alprazolam is a water-insoluble weak base (pKa 2.41) which forms a somewhat water-soluble cation in acidic solution. Solubility (S) of alprazolam at several different pH levels was determined in aqueous solutions containing 10% (w/v) 2-hydroxypropyl- β -cyclodextrin (HP β CD) of molar substitution (MS) = 0.3. Excess amount of the drug was added to the aqueous HP β CD solution and the suspension formed heated in a sealed container in an autoclave (120-140°C for 20-40 minutes). After equilibration at room temperature (22-23°C) for seven days, the suspension was filtered through a 0.45 μ m membrane filter, diluted with aqueous methanolic solution and the amount of dissolved alprazolam determined by a high pressure liquid chromatographic method (HPLC). FIG. 2 illustrates the effect of pH on the solubility of alprazolam (pKa 2.4) in aqueous 10% (w/v) HP β CD solutions at room temperature. The results set forth in FIG. 2 show significant enhancement in the HP β CD solubilization (i.e. the efficiency of the complexation) of the drug at a pH at which the drug is mainly in the ionized form. The sharp increase in the solubility can, however, only partly be explained by the ionization of the alprazolam molecule.

-23-


Example 3

Several drugs which have a nitrogen-containing heterocycle in their structure are known to undergo reversible ring-opening which frequently is pH dependent. For example, barbituric acids undergo reversible ring cleavage (H.J. Roth, K. Eger and R. Troschütz, *Pharmaceutical Chemistry. Volume 2. Drug Analysis*. Ellis Horwood, 1991, pp. 308-309):



Another example of such reversible ring-opening is the opening of cyclic imines through formation of an aldehyde or ketone and a primary amine:

Another example of such reversible ring-opening is the opening of cyclic imines through formation of an aldehyde or ketone and a primary amine:



An example of such structure is the 1*H*-1,4-diazepine ring which, for example, is an essential structure of the benzodiazepine derivatives. These structural changes are pH-dependent and reversible, and it is known that the open form frequently co-exists with the closed one in several commercial products. One example is the *iv* solution of midazolam (Dormicum™ from F. Hoffmann-LaRoche & Ltd,

-24-

Switzerland) where the drug is partly in the open form (M. Gerecke, "Chemical structure and properties of midazolam compared with other benzodiazepines", *Br. J. Clin. Pharmac.*, 11S-16S (1983)). However, the open form of midazolam is rapidly converted to the closed one upon *iv* administration.

5 We have determined the effect of pH and cyclodextrins, i.e. HP β CD MS 0.3, sulfobutylether β -cyclodextrin (SBE β CD) with degree of substitution (DS) = 6.4, α -cyclodextrin (α CD) and γ -cyclodextrin (γ CD) on the ring-opening of several benzodiazepines. The cyclodextrin concentration was 10% (w/v) and the benzodiazepine concentration was 1×10^{-4} M. The concentration of the closed form
10 was determined immediately after dissolving the benzodiazepine in the aqueous cyclodextrin solution and again 24 hours later (i.e. after equilibration at 23°C). Preliminary experiments had shown that equilibrium between the closed and the open form was attained within 3 hours at 23°C.

 It is clear from the results displayed in Table 3 below that a large fraction
15 of the benzodiazepines (over 50% at pH below 2) are in the open form at low pH and that the fraction of open form frequently increases upon addition of cyclodextrin to the aqueous solution. For example, at pH 3 about 60% of alprazolam in aqueous HP β CD solution is in the open form. This will increase the apparent intrinsic solubility (S_0). This increase in S_0 will result in enhanced
20 complexation efficiency. The observed increase in the complexation efficiency will result in enhanced cyclodextrin solubilization of the benzodiazepines in aqueous solutions.

-25-

Table 3. The effect of pH and cyclodextrins on the fraction of the open form of several benzodiazepines at room temperature (approx. 23°C).

	Benzodiazepine	Cyclodextrin	pH	Fraction open	
5	Alprazolam (pKa 2.4)	None	2	0.82	
			3	0.56	
			4	0.33	
10		HPβCD	2	0.89	
			3	0.60	
			4	0.23	
		SBEβCD	2	0.96	
			3	0.84	
			4	0.33	
15		αCD	2	0.94	
			3	0.79	
			4	0.25	
		γCD	2	0.81	
			3	0.41	
			4	0.42	
20	Diazepam (pKa 3.3)	None	2	0.30	
3			0.23		
4			0.15		
25		HPβCD	2	0.65	
			3	0.29	
			4	0.15	
		SBEβCD	2	0.63	
			3	0.56	
			4	0.22	
30		αCD	2	0.67	
			3	0.51	
			4	0.13	
		γCD	2	0.41	
			3	0.17	
			4	0.13	
35					

Table cont. on next page.

-26-

Benzodiazepine		Cyclodextrin	pH	Fraction open
5	Midazolam (pKa 6.2)	None	2	0.74
			3	0.28
			4	0.18
		HP β CD	2	0.56
			3	0.18
			4	0.23
		SBE β CD	2	0.81
			3	0.39
			4	0.11
10	Midazolam (pKa 6.2)	α CD	2	0.79
			3	0.32
			4	0.10
		γ CD	2	0.61
			3	0.21
			4	0.17
		None	2	0.53
			3	0.08
			4	0.00
15	Triazolam (pKa between 2 and 3)	HP β CD	2	0.51
			3	0.09
			4	0.00
		SBE β CD	2	0.71
			3	0.25
			4	0.00
		α CD	2	0.75
			3	0.23
			4	0.00
20	Triazolam (pKa between 2 and 3)	γ CD	2	0.33
			3	0.01
			4	0.00

-27-

Example 4

Midazolam is a water-insoluble weak base (pKa 6.2) which forms a somewhat water-soluble cation in acidic solution. Solubility (S) of midazolam at several different pH levels was determined in: a) pure aqueous buffer solutions (i.e. without HP β CD and HPMC); b) aqueous buffer solutions containing 10% (w/v) 2-hydroxypropyl- β -cyclodextrin (HP β CD) of molar substitution (MS) = 0.3; and c) aqueous solutions containing 10% (w/v) 2-hydroxypropyl- β -cyclodextrin (HP β CD) of molar substitution (MS) = 0.3 and 0.10% (w/v) hydroxypropyl methylcellulose (HPMC) 4000. Excess amount of the drug was added to the aqueous solution and the suspension formed was heated in a sealed container in an autoclave (120-140°C for 20-40 minutes). After equilibration at room temperature (22-23°C) for seven days, the suspension was filtered through a 0.45 μ m membrane filter, diluted with aqueous methanolic solution and the amount of dissolved midazolam determined by a high pressure liquid chromatographic method (HPLC). FIG. 3 illustrates the effect of pH (i.e. the ring-opening) on the solubility of midazolam (pKa 6.2) in pure aqueous buffer solutions (●), aqueous buffer solutions containing 10% (w/v) HP β CD (■), and aqueous buffer solutions containing both 10% (w/v) HP β CD and 0.10% (w/v) HPMC (◆) at room temperature. The results set forth in FIG. 3 show significant enhancement in the HP β CD solubilization (i.e. the efficiency of the complexation) of the drug at pH levels where the drug exists partly in the open form. Addition of HPMC significantly improves the efficiency.

Example 5

Solubility (S) of midazolam at several different pH levels was determined in: a) pure aqueous buffer solutions (i.e. without cyclodextrin, polymer or acetic acid); b) aqueous buffer solutions containing 10% (v/v) acetic acid as a co-solvent; c) aqueous buffer solutions containing 10% (w/v) sulfobutylether β -cyclodextrin

-28-

(SBE β CD) and 10% (v/v) acetic acid as a co-solvent; and d) aqueous buffer solutions containing 10% (w/v) 2-hydroxypropyl- β -cyclodextrin (HP β CD), 0.10% (w/v) hydroxypropyl methylcellulose (HPMC) and 10% (v/v) acetic acid as a co-solvent. Excess amount of the drug was added to the aqueous HP β CD solution and the suspension formed was heated in a sealed container in an autoclave (120-140°C for 20-40 minutes). After equilibration at room temperature (22-23°C) for seven days, the suspension was filtered through a 0.45 μ m membrane filter, diluted with aqueous methanolic solution and the amount of dissolved midazolam determined by a high pressure liquid chromatographic method (HPLC). FIG. 4 illustrates the effects of cyclodextrins, pH and 10% (v/v) acetic acid on the solubility of midazolam in aqueous solutions: pure aqueous buffer solution (\blacktriangle); aqueous 10% (v/v) acetate solution (\bullet); 10% (w/v) HP β CD solution containing 0.10% (w/v) HPMC in aqueous 10% (v/v) acetic acid solution (\blacksquare); 10% (w/v) aqueous SBE β CD solution in aqueous 10% (v/v) acetate (\blacklozenge). The results set forth in FIG. 4 show that addition of 10% (v/v) acetic acid significantly improves the complexation. Addition of the acetic acid increases the value of S_0 without having any significant effect on the value of K_C , which significantly improves the complexation efficiency and, consequently, enhances the cyclodextrin solubilization of the drug. Midazolam carries a positive charge at acidic pH and, thus, the negatively charged SBE β CD forms a more stable complex than the uncharged HP β CD with midazolam at these conditions. Addition of 10% (v/v) acetic acid as a co-solvent resulted in a small decrease in the fraction of the open ring form of the drug.

Example 6

Female hairless mice were sacrificed by cervical dislocation and their full-thickness skins removed. The outer surface of the skin was rinsed with 35% (v/v) methanol in water and subsequently with distilled water to remove any

-29-

contamination. The skin was placed in Franz diffusion cells. The receptor phase consisted of phosphate buffer saline pH 7.4. The skin diffusion cells were stirred with a magnetic bar and kept at 37°C by circulating water through an external jacket. The donor phase (2.0 ml) consisted of a solution of the drug in aqueous 7% (w/v) SBE β CD solution pH 3.3, or aqueous cyclodextrin solution where the pH had been raised from 3.3 to 4.1 (by addition of NaOH) before it was applied to the skin. The alprazolam concentration in the donor phase was 1.85 mg/ml at pH 3.3. Samples (200 μ l) of receptor phase were removed from the cells at various time intervals up to 48 hours and replaced with a fresh buffer solution. The samples were kept frozen until analyzed by HPLC. The flux was calculated from the linear part of each permeability profile and the permeability coefficient obtained by dividing the flux with the concentration of dissolved drug in the donor phase. The results set forth in Table 4 show clearly that raising the pH from 3.3 to 4.1 increases the flux through biological membranes such as hairless mouse skin.

Table 4. The flux of alprazolam through hairless mouse skin. The donor phase consisted of aqueous pH 3.3 buffer solution containing 7% (w/v) SBE β CD saturated with the drug. In one case the pH of the donor phase was kept constant at pH 3.3, but in the other case the pH was raised to 4.1 (by addition of NaOH) before it was applied to the skin. The alprazolam concentration in the donor phase was 1.85 mg/ml at pH 3.3.

Donor phase	Flux (mg/cm ² /h)	Ratio
Without increasing the pH	3.91×10^{-4}	1.0
Increasing the pH from 3.3 to 4.1	4.56×10^{-4}	1.2

-30-

Example 7

The effect of cyclodextrins and organic solvents on the rate of diazepine ring-closure of several selected benzodiazepines was investigated. Stock solutions containing 1.0×10^{-3} M of the benzodiazepine in 0.10 M aqueous hydrochloric acid solution (pH approx. 1.1) were prepared and stored at 37.0°C. The benzodiazepines were in the ring-open form in these stock solutions. Aqueous 0.50 M tris buffer (pH 7.50) solution was prepared. The observed first-order rate constant for the closing (i.e. formation) of the benzodiazepine ring was determined in the following reaction media: a) pure aqueous tris buffer solution; b) aqueous tris buffer solution containing 10% (w/v) cyclodextrin; c) tris buffer solution containing 10% (w/v) cyclodextrin and 10% (v/v) ethanol (EtOH); d) tris buffer solution containing 10% (w/v) cyclodextrin and 50% (v/v) EtOH; e) tris buffer solution containing 10% (w/v) cyclodextrin and 10% (v/v) dimethylsulfoxide (DMSO); and f) tris buffer solution containing 10% (w/v) cyclodextrin and 50% (w/v) DMSO. The stock solution (30 μ l) was added to 1.50 ml of the reaction media which had previously been equilibrated to 37.0°C and the first-order rate constant for the appearance of the closed form determined from the appearance of the closed form as observed on HPLC. Tables 5, 6 and 7 show the effects of cyclodextrins, EtOH and DMSO on the observed first-order rate constant for the regeneration of alprazolam, triazolam and midazolam, respectively. In pure aqueous buffer solutions, addition of EtOH and DMSO decreases somewhat the rate of ring closure, at least in the case of alprazolam and midazolam. Addition of cyclodextrin or the organic solvents have insignificant effect on the pH under these conditions. The dielectric constant of the reaction medium will, however, decrease upon addition of the organic solvents. It is possible that this decrease in the dielectric constant will reduce the ability of the reaction media to stabilize the transition state which could explain the decrease in the observed rate constant. Addition of cyclodextrin decreased significantly, in all cases, the rate of ring

-31-

closure. The cyclodextrins formed stable complexes with the ring-open form of the drug and, thus, the rate decreased upon addition of cyclodextrin. Addition of EtOH or DMSO to the cyclodextrin-containing reaction media resulted in increase in the rate, compared to reaction media containing only cyclodextrin, which could be due to decreased complexation of the diazepine ring-open form. EtOH and DMSO will compete with the diazepine ring-open form for a space in the cyclodextrin cavity resulting in decreased complexation.

Table 5. The effect of cyclodextrins, ethanol (EtOH) and dimethylsulfoxide (DMSO) on the first-order rate constant for the formation of the diazepine ring, i.e. regeneration of alprazolam, at pH 7.5 and 37°C.

Cyclodextrin	The observed first-order rate constant $\times 10^2$ (min^{-1})				
	Pure water	10% EtOH	50% EtOH	10% DMSO	50% DMSO
No CD	14.2	11.5	7.24	9.68	10.7
10% RM β CD	2.97	4.90	6.70	3.97	7.92
10% HP β CD	3.30	5.23	7.07	4.44	8.57
10% SBE β CD	3.11	5.18	5.82	4.77	9.36

Table 6. The effect of cyclodextrins, ethanol (EtOH) and dimethylsulfoxide (DMSO) on the first-order rate constant for the formation of the diazepine ring, i.e. regeneration of triazolam, at pH 7.5 and 37°C.

Cyclodextrin	The observed first-order rate constant $\times 10^{-2}$ (min^{-1})				
	Pure water	10% EtOH	50% EtOH	10% DMSO	50% DMSO
No CD	1.32	1.31	1.84	1.28	1.37
10% RM β CD	0.64	0.92	1.00	0.78	1.12
10% HP β CD	0.66	0.92	1.02	0.79	1.14
10% SBE β CD	0.58	0.82	0.97	0.73	1.13

-32-

Table 7. The effect of cyclodextrins, ethanol (EtOH) and dimethylsulfoxide (DMSO) on the first-order rate constant for the formation of the diazepine ring, i.e. regeneration of midazolam, at pH 7.5 and 37°C.

Cyclodextrin	The observed first-order rate constant $\times 10^{-2}$ (min ⁻¹)				
	Pure water	10% EtOH	50% EtOH	10% DMSO	50% DMSO
No CD	17.9	12.6	8.41	13.8	10.9
10% RM β CD	3.05	4.24	6.99	4.94	8.48
10% HP β CD	2.77	3.86	6.53	3.36	8.40
10% SBE β CD	1.30	3.30	6.50	2.24	8.55

Example 8

The bioavailability of midazolam in a nasal spray according to the invention was evaluated. The composition of the midazolam nasal spray was as follows: midazolam 1.70% (w/v), sulfobutylether β -cyclodextrin sodium salt (Captisol®) 14.00% (w/v), benzalkonium chloride 0.02% (w/v), sodium edetate (EDTA tetrasodium) 0.10% (w/v), hydroxypropyl methylcellulose 0.10% (w/v), phosphoric acid 0.50% (v/v), sodium hydroxide *quantum satis* ad pH 4.35 in purified water. The intravenous (iv) dose was fixed at 2 mg (Dormicum™ 5 mg/ml iv solution from F. Hoffmann-La Roche & Ltd., Switzerland) but the intranasal (in) dose was 0.06 mg/kg or 4.84 mg (285 μ l nasal spray) on the average. This was a cross-over study where each individual received both the iv and in formulation (via nasal spray) with a one week resting period between administrations. Serum samples were collected at various time points after administration of the drug and the midazolam concentration determined with an HPLC method. Fig. 5 illustrates the concentration profile of midazolam in serum after administration of 2 mg of midazolam *intravenously* (○) or 4.8 mg of midazolam *intranasally* (Δ). Each point represents the mean value; error bars represent standard deviation. The bioavailability of midazolam after intranasal

-33-

administration was determined to be 61 % and the mean C_p^{\max} was determined to be 52 ng/ml at 12 min after intranasal administration of the drug. Sedation was not observed after the iv administration but sedation was observed in all three individuals within 10 min after intranasal administration of the drug. This
5 sedation lasted for about one and one-half hours. Insignificant irritation was observed in the three individuals tested after intranasal administration of the drug.

While the invention has been described in terms of various preferred embodiments, the person skilled in the art will appreciate that various modifications, substitutions, omissions and changes can be made without departing
10 from the spirit thereof. Accordingly, it is intended that the scope of the present invention be limited solely by the scope of the following claims, including equivalents thereof.

WHAT IS CLAIMED IS:

1. A method for enhancing the complexation efficiency of a drug with cyclodextrin, said drug having a structure comprising at least one heterocyclic ring having a total of from 4 to 7 ring atoms, of which from 1 to 3 are hetero ring
5 atoms, each of said hetero ring atoms being selected from nitrogen, oxygen and sulfur, said ring being a cyclic imine, enamine, lactone, lactam, thiolactam, anhydride, imide, hemiacetal or hemiketal, said method comprising subjecting said drug to chemically reversible ring-opening so that at least 0.1 % by weight thereof is in ring-opened form, and complexing said drug with cyclodextrin.
- 10 2. A method according to Claim 1, comprising complexing said drug with cyclodextrin in an aqueous medium under conditions which effect chemically reversible ring-opening of at least 0.1 % by weight of said drug.
- 15 3. A method for enhancing the availability of a drug following administration of a cyclodextrin-drug complex to a warm-blooded animal in need of same, said drug having a structure comprising at least one heterocyclic ring having a total of from 4 to 7 ring atoms of which from 1 to 3 are hetero ring
atoms, each of said hetero ring atoms being selected from nitrogen, oxygen and sulfur, said ring being a cyclic imine, enamine, lactone, lactam, thiolactam, anhydride, imine, hemiacetal or hemiketal, said method comprising complexing
20 said drug with cyclodextrin in an aqueous medium under conditions which effect chemically reversible ring-opening of at least 0.1 % by weight of said drug to enhance the complexation efficiency, followed by administering the cyclodextrin-drug complex thus obtained to said animal under conditions which reduce the complexation efficiency.

-35-

4. A method for enhancing the availability of a basic drug (i.e., a proton acceptor) following administration of a cyclodextrin-drug complex to a warm-blooded animal in need of same, said basic drug having a structure comprising at least one heterocyclic ring having a total of from 4 to 7 ring atoms, of which from 1 to 3 are hetero ring atoms, each of said hetero ring atoms being selected from nitrogen, oxygen and sulfur, said ring being a cyclic imine, enamine, lactone, lactam, thiolactam, anhydride, imide, hemiacetal or hemiketal, said method comprising subjecting said basic drug to complexation in an aqueous medium at a pH level below the $pK_a + 2$ value of said basic drug to enhance the complexation efficiency, followed by administering the cyclodextrin-drug complex thus obtained to said animal under conditions which reduce the complexation efficiency.

5. A method for enhancing the availability of an acidic drug following administration of a cyclodextrin-drug complex to a warm-blooded animal in need of same, said acidic drug having a structure comprising at least one heterocyclic ring having a total of 4 to 7 ring atoms, of which from 1 to 3 are hetero ring atoms, each of said hetero ring atoms being selected from nitrogen, oxygen and sulfur, said ring being a cyclic imine, enamine, lactone, lactam, thiolactam, anhydride, imide, hemiacetal or hemiketal, said method comprising subjecting said acidic drug to complexation in an aqueous medium at a pH level above the $pK_a - 2$ value of said acidic drug to enhance the complexation efficiency, followed by administering the cyclodextrin-drug complex thus obtained to said animal under conditions which reduce the complexation efficiency.

6. A method according to any one of Claims 2 to 4, wherein the complexation is conducted under conditions which effect chemically reversible ring-opening of at least 1 % by weight of said drug, preferably wherein the

-36-

complexation is conducted at a pH level which affords ring-opening of at least 5% by weight of said drug.

7. A method according to Claim 5, wherein the complexation is conducted under conditions which effect chemically reversible ring-opening of at least 1% by weight of said drug, preferably wherein the complexation is conducted at a pH level which affords ring-opening of at least 5% by weight of said drug.

8. A method according to any one of Claims 1-4 and 6, wherein the complexation is conducted at a pH level of below about 5.

9. A method according to any one of Claims 1-3, 6 and 8, wherein the drug is a basic drug.

10. A method according to any one of Claims 1-4, 6, 8, and 9, wherein the drug is a benzodiazepine.

11. A method according to Claim 10, wherein the benzodiazepine is alprazolam, brotizolam, chlordiazepoxide, clobazam, clonazepam, clorazepam, demoxazepam, flumazenil, flurazepam, halazepam, midazolam, nordazepam, medazepam, diazepam, nitrazepam, oxazepam, midazepam, lorazepam, prazepam, quazepam, triazolam, temazepam or loprazolam.

12. A method according to any one of Claims 1-4, 6 and 8-11, wherein the cyclodextrin is hydroxypropyl- β -cyclodextrin, β -cyclodextrin sulfobutyl ether, β -cyclodextrin, γ -cyclodextrin or hydroxypropyl- γ -cyclodextrin.

-37-

13. A method according to Claim 5 or 7, wherein the cyclodextrin is hydroxypropyl- β -cyclodextrin, β -cyclodextrin sulfobutyl ether, β -cyclodextrin, γ -cyclodextrin or hydroxypropyl- γ -cyclodextrin.

14. A method according to any one of Claims 10-12, followed by
5 formulating the cyclodextrin-drug complex thus obtained as a nasal spray, sublingual tablet or parenteral solution.

15. A method according to Claim 14, wherein the nasal spray, sublingual tablet or parenteral solution is formulated to be suitable for use in producing a sedative, anti-anxiety, anticonvulsant or muscle relaxant effect,
10 preferably for use as a pre-anaesthetic medication, or to supplement anaesthesia, to induce and maintain anaesthesia or to induce a hypnotic effect.

16. A method according to Claim 15, wherein the benzodiazepine is alprazolam, clonazepam, lorazepam, midazolam or triazolam.

17. A method according to any one of Claims 1-4, 6 and 8-12, wherein
15 the complexation is conducted at a pH level between about 3 and about 5.

18. A method according to Claim 1 or 2, wherein the drug is an acidic drug and the complexation is conducted under conditions which effect chemically reversible ring-opening of at least 1% by weight of said drug, preferably wherein the complexation is conducted at a pH level which affords ring-opening of at least
20 5% by weight of said drug.

19. A method according to Claim 1 or 2, wherein the drug is a barbituric acid derivative, a hydantoin, a pyrazole derivative, an imidazole

-38-

derivative, a pyrimidine derivative or a purine derivative, and the complexation is conducted under conditions which effect chemically reversible ring-opening of at least 1 % by weight of said drug, preferably wherein the complexation is conducted at a pH level which affords ring-opening of at least 5 % by weight of said drug.

- 5 20. A method according to Claim 19, wherein the barbituric acid derivative is barbital, butobarbital, amobarbital, phenobarbital, aprobarbital, secobarbital, crotylbarbital, cyclobarbital, phenobarbital, hexobarbital, methylphenobarbital, thiopental, isopropylbromallylbarbituric acid, or cyclohexenylallylthiobarbituric acid, or a salt thereof; or wherein the hydantoin is
10 phenytoin; or wherein the pyrazole derivative is phenazone, propylphenazone, metamidazole, phenylbutazone, oxyphenbutazone or sulfinpyrazone; or wherein the imidazole derivative is histamine, miconazole, pilocarpine, naphazoline or clonidine; or wherein the pyrimidine derivative is thiamine, trimethoprim, orotic acid, methylthiouracyl or prothiouracyl; or wherein the purine derivative is
15 caffeine, theophylline, etophylline, proxyphylline or theobromine.

21. A method according to Claim 3, wherein the cyclodextrin-drug complex is administered in the form of an aqueous solution or a hydrogel.

22. A method according to Claim 21, wherein the cyclodextrin-drug complex is administered as a nasal spray or nasal drops.

- 20 23. A method according to Claim 21, wherein the cyclodextrin-drug complex is administered as a parenteral solution.

24. A method according to Claim 21, wherein the aqueous solution is at a pH level of below about 6 and is administered as a nasal spray.

-39-

25. A method according to Claim 24, wherein the pH level of the nasal spray is below about 4.7, preferably wherein the pH level of the nasal spray is between about 3 and about 4.7.

5 26. A method according to Claim 3, wherein the drug is a benzodiazepine, the complexation is conducted at a pH level which affords ring-opening of at least 5% by weight of said drug, said pH level being below about 5, and the cyclodextrin-drug complex is administered as a solid.

10 27. A method according to Claim 26, wherein the solid cyclodextrin-drug complex is administered as a tablet formulated for oral, buccal or sublingual administration.

28. A method according to Claim 3, wherein the water is removed from the aqueous complexation medium after formation of the cyclodextrin-drug complex.

15 29. A method according to Claim 4, wherein the drug is a benzodiazepine and the complexation is carried out at a pH level which affords ring-opening of at least 5% by weight of said drug and in the presence of from about 0.001 to about 5% (weight/volume) of a pharmacologically inactive, pharmaceutically acceptable water-soluble polymer at a temperature of from about 30°C to about 150°C.

20 30. A method according to Claim 29, wherein the polymer is a cellulose derivative or a polyvinyl polymer.

-40-

31. A method according to Claim 30, wherein the polymer is methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl methylcellulose, hydroxypropyl ethylcellulose, hydroxyethyl ethylcellulose, sodium carboxymethylcellulose or
5 polyvinylpyrrolidone.

32. A method according to Claims 4 or 29, wherein the drug is a benzodiazepine and the complexation is carried out at a pH level which affords ring-opening of at least 5% by weight of said drug and in the presence of at least one member of the group consisting of acetic acid and its pharmaceutically
10 acceptable salts, the acetate-water ratio of the aqueous complexation medium being from about 1:1000 to about 2:1.

33. A method according to Claim 32, wherein the drug is midazolam and the cyclodextrin is hydroxypropyl- β -cyclodextrin, β -cyclodextrin sulfobutyl ether, β -cyclodextrin, γ -cyclodextrin or hydroxypropyl- γ -cyclodextrin.

1/5




Figure 1

2/5




Figure 2

3/5




Figure 3

4/5




Figure 4

5/5




Figure 5

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IS 99/00003

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: A61K 31/715, C08B 37/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: A61K, C08B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	International Journal of Pharmaceutics, Volume 73, 1991, Injoon Oh et al, "Stability and solubilization of oxathiin carboxanilide, a novel anti-HIV agent" page 23 - page 31	1-9,12-13, 17-18,21,23, 28,30,31,33
A	--	10,11,14-16, 19,20,22, 24-27,32
A	US 5324718 A (THORSTEINN LOFTSSON), 28 June 1994 (28.06.94)	1-33
A	US 5472954 A (THORSTEINN LOFTSSON), 5 December 1995 (05.12.95)	1-33

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

7 June 1999

Date of mailing of the international search report

19-06-1999

Name and mailing address of the ISA

Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer:

Eva Johansson/Els
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IS 99/00003

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 9402518 A1 (THE UNIVERSITY OF KANSAS), 3 February 1994 (03.02.94) -- -----	1-33

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IS99/00003

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 3-5, 7, 13, 21-33
because they relate to subject matter not required to be searched by this Authority, namely:
See PCT Rule 39.1(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

03/05/99

International application No.

PCT/IS 99/00003

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5324718 A	28/06/94	AT 177647 T DE 69323937 D EP 0579435 A,B SG 49182 A US 5472954 A	15/04/99 00/00/00 19/01/94 18/05/98 05/12/95
US 5472954 A	05/12/95	AT 177647 T DE 69323937 D EP 0579435 A,B SG 49182 A US 5324718 A	15/04/99 00/00/00 19/01/94 18/05/98 28/06/94
WO 9402518 A1	03/02/94	AU 672814 B AU 4779993 A CA 2119154 A,C EP 0620828 A JP 6511513 T US 5376645 A	17/10/96 14/02/94 03/02/94 26/10/94 22/12/94 27/12/94

Form PCT/ISA/210 (patent family annex) (July 1992)